COBALT advised EFPIA and IFPA in signing a landmark joint working agreement with the Lithuanian Ministry of Health
COBALT advised EFPIA and IFPA in signing a landmark joint working agreement with the Lithuanian Ministry of Health
Life Sciences
2014 — 07 — 21

COBALT advised EFPIA, the European Federation of Pharmaceutical Industries and Associations (its Lithuanian member – the Innovative Pharmaceutical Industry Association (IFPA)) – in signing a significant new Joint Working Agreement with the Lithuanian Ministry of Health. The Agreement will pave the way for future health protection and growth improvement in Lithuania.

This is the first-of-a-kind agreement between the Lithuanian Ministry of Health and pharmaceutical industry representatives. The Agreement provides for a range of measures to safeguard future innovation and healthcare, including the establishment of a specific "Reimbursement Budget" that will reflect and be proportionate to both GDP growth and an increase in overall public health care spending. 

EFPIA Director General Richard Bergström commented: "Our industry has entered into a number of agreements with European governments, but the Lithuanian agreement has achieved a new progressive, gold standard in collaboration for better health outcomes. It signifies a new dawn in our industry’s partnerships, as it delivers a much more comprehensive solution to meeting the health and economic needs of citizens. I urge other nations to learn from the Lithuanian approach."

EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world. 

IFPA started its activity in October 1997 and currently it has 17 members – innovative pharmaceutical companies and their representative offices registered in Lithuania. It links up pharmaceutical companies developing new, patent medicines and promoting ethical business principles. The member companies of the Association recognise and follow the Code of Ethics for Pharmaceutical Marketing in their daily activities. 

COBALT drafted and coordinated the Agreement and represented EFPIA and IFPA during negotiations. The project was led by Partner Žilvinas Kvietkus.

For more information please click here >>